KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation (IS) (2021 - 2025)

BioNTech SE's Share-based Compensation (IS) history spans 5 years, with the latest figure at -$7.0 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation (IS) rose 40.04% to -$7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$28.7 million, a 83.04% increase, with the full-year FY2025 number at -$28.6 million, up 82.69% from a year prior.
  • Share-based Compensation (IS) hit -$7.0 million in Q4 2025 for BioNTech SE, down from -$4.9 million in the prior quarter.
  • Over the last five years, Share-based Compensation (IS) for BNTX hit a ceiling of -$1.7 million in Q3 2022 and a floor of -$778.9 million in Q1 2023.
  • Historically, Share-based Compensation (IS) has averaged -$63.4 million across 5 years, with a median of -$5.4 million in 2023.
  • Biggest five-year swings in Share-based Compensation (IS): tumbled 38456.63% in 2023 and later surged 99.67% in 2024.
  • Tracing BNTX's Share-based Compensation (IS) over 5 years: stood at -$2.7 million in 2021, then plummeted by 1650.25% to -$48.1 million in 2022, then surged by 88.8% to -$5.4 million in 2023, then tumbled by 116.51% to -$11.6 million in 2024, then soared by 40.04% to -$7.0 million in 2025.
  • Business Quant data shows Share-based Compensation (IS) for BNTX at -$7.0 million in Q4 2025, -$4.9 million in Q3 2025, and -$13.0 million in Q2 2025.